Protagenic Total Other Income Expense Net from 2010 to 2024

PTIXW Stock  USD 0.01  0.0005  5.75%   
Protagenic Therapeutics Total Other Income Expense Net yearly trend continues to be fairly stable with very little volatility. Total Other Income Expense Net will likely drop to about -497.2 K in 2024. During the period from 2010 to 2024, Protagenic Therapeutics Total Other Income Expense Net regression line of quarterly data had r-squared of  0.21 and coefficient of variation of (245.28). View All Fundamentals
 
Total Other Income Expense Net  
First Reported
1995-09-30
Previous Quarter
60.8 K
Current Value
11.3 K
Quarterly Volatility
12.4 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Protagenic Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protagenic Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 26.8 K, Interest Expense of 137.6 K or Selling General Administrative of 1.1 M, as well as many indicators such as Price To Sales Ratio of 0.28, Dividend Yield of 0.0 or PTB Ratio of 1.11. Protagenic financial statements analysis is a perfect complement when working with Protagenic Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Protagenic Therapeutics Correlation against competitors.
For more information on how to buy Protagenic Stock please use our How to Invest in Protagenic Therapeutics guide.

Latest Protagenic Therapeutics' Total Other Income Expense Net Growth Pattern

Below is the plot of the Total Other Income Expense Net of Protagenic Therapeutics over the last few years. It is Protagenic Therapeutics' Total Other Income Expense Net historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protagenic Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Other Income Expense Net10 Years Trend
Slightly volatile
   Total Other Income Expense Net   
       Timeline  

Protagenic Total Other Income Expense Net Regression Statistics

Arithmetic Mean(104,033)
Coefficient Of Variation(245.28)
Mean Deviation210,326
Median2,283
Standard Deviation255,175
Sample Variance65.1B
Range832.4K
R-Value(0.46)
Mean Square Error55.5B
R-Squared0.21
Significance0.09
Slope(26,022)
Total Sum of Squares911.6B

Protagenic Total Other Income Expense Net History

2024-497.2 K
2023-473.5 K
2022 2283.0
2021-382.5 K
2020 2876.0
2019335.2 K
2018-246.2 K

About Protagenic Therapeutics Financial Statements

Protagenic Therapeutics investors use historical fundamental indicators, such as Protagenic Therapeutics' Total Other Income Expense Net, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protagenic Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Other Income Expense Net-473.5 K-497.2 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Protagenic Stock Analysis

When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.